UroGen Pharma (URGN) FCF Margin (2017 - 2026)
UroGen Pharma (URGN) posted quarterly FCF Margin of 93.5% for Q1 2026, up 11291.0% year-on-year from N/an in Q1 2025, and up 3.67% on a QoQ basis from 97.07% in Q4 2025.
UroGen Pharma (URGN) FCF Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported FCF Margin for 10 consecutive years, with 93.5% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin rose 11291.0% year-over-year to 93.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123.04% (down 730.0% YoY) and the FY2025 annual result came in at 152.13%, down 4668.0% from the prior year.
- FCF Margin climbed to 93.5% in Q1 2026 per URGN's latest filing, from 97.07% in the prior quarter.
- Over the last five years, FCF Margin for URGN reached as high as 55.18% in Q4 2023 and fell as low as 206.41% in Q1 2025.
- A 5-year average of 124.46% and a median of 112.87% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 19176 bps — and 2025, when it slumped 6693 bps.
- Year by year, FCF Margin stood at 121.72% in 2022, then soared by 55 bps to 55.18% in 2023, then dropped by 2 bps to 56.33% in 2024, then tumbled by 72 bps to 97.07% in 2025, then rose by 4 bps to 93.5% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 93.5%, 97.07%, and 175.49% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -93.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.50% |
| Dec 31, 2025 | -97.07% |
| Sep 30, 2025 | -175.49% |
| Jun 30, 2025 | -166.24% |
| Mar 31, 2025 | -206.41% |
| Dec 31, 2024 | -56.33% |
| Sep 30, 2024 | -108.56% |
| Jun 30, 2024 | -106.75% |
| Mar 31, 2024 | -163.97% |
| Dec 31, 2023 | -55.18% |
| Sep 30, 2023 | -79.28% |
| Jun 30, 2023 | -94.28% |
| Mar 31, 2023 | -152.56% |
| Dec 31, 2022 | -121.72% |
| Sep 30, 2022 | -112.87% |
| Jun 30, 2022 | -147.40% |
| Mar 31, 2022 | -178.16% |
| Dec 31, 2021 | -120.67% |
| Sep 30, 2021 | -167.59% |
| Jun 30, 2021 | -151.04% |